Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.56 |
| ▸ | MAPT | P10636 | 10/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | CNR2 | P34972 | 1/20 | 0.54 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.47 |
| ▸ | GPR183 | P32249 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2432797 | 0.86 | CNR1 (0.58) | CNR1SMN1; SMN2MAPTKMT2AALDH1A1 | |
| SCHEMBL2435843 | 0.85 | CNR1 (0.60) | CNR1SMN1; SMN2MAPTKMT2AALDH1A1 | |
| SCHEMBL2436162 | 0.85 | CNR1 (0.60) | CNR1SMN1; SMN2MAPTKMT2AALDH1A1 | |
| SCHEMBL3158144 | 0.82 | MAPT (0.55) | CNR1SMN1; SMN2MAPTKMT2AALDH1A1 | |
| SCHEMBL30794573 | 0.81 | CNR1 (0.51) | CNR1SMN1; SMN2MAPTKMT2AALDH1A1 | |
| SCHEMBL2435114 | 0.81 | CNR1 (0.51) | CNR1SMN1; SMN2MAPTKMT2AALDH1A1 | |
| SCHEMBL2437628 | 0.80 | KCNQ2 (0.54) | SMN1; SMN2MAPTALDH1A1NPSR1 | |
| SCHEMBL30795862 | 0.80 | CNR1 (0.52) | CNR1SMN1; SMN2MAPTKMT2AALDH1A1 | |
| SCHEMBL2435116 | 0.80 | CNR1 (0.52) | CNR1SMN1; SMN2MAPTKMT2AALDH1A1 | |
| SCHEMBL19623726 | 0.79 | EPHX1 (0.48) | MAPTKMT2AALDH1A1MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1947093-B9 | Substituted morpholine and thiomorpholine derivatives | LUNDBECK & CO AS H (DK) | 2010-03-03 | — | — | EP | claimed |
| EP-1947093-B1 | Substituted morpholine and thiomorpholine derivatives | LUNDBECK & CO AS H (DK) | 2009-09-23 | — | — | EP | claimed |
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| EP-4580679-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | Biohaven Therapeutics Ltd. (VG) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| US-8012962-B2 | Substituted thiomorpholine derivatives | H. LUNDBECK A/S (DK) | 2011-09-06 | — | — | US | disclosed |
| US-7632835-B2 | 2-Cyclopentyl-N-(2-bromo-6-trifluoromethyl-4-(thio)morpholin-4-yl-phenyl)-acetamide; potent openers of the KCNQ family of potassium ion channels; antiepileptic agents; anticonvulsants; anxiolytic agents; neurodegenerative disorders; analgesics for headaches, neuropathic pain; bipolar disorders | H. LUNDBECK A/S (DK) | 2009-12-15 | — | — | US | disclosed |
| US-20090137571-A1 | SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137571-A1 | SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES | OPRM1, OPRK1, OPRD1 | CNR1 111/4885SMN1; SMN2 1387/4885MAPT 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.